Atogepant 60 mg
Atogepant 60 mg is a pharmaceutical drug with 8 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
0
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
5 of 5 finished
0.0%
0 ended early
3
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
Long-term Atogepant in Real-world Practice
Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
Clinical Trials (8)
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
Long-term Atogepant in Real-world Practice
Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8